

Article

Synthesis of gamma-Lactams by Mild, o-Benzoquinone-Induced Oxidation of Pyrrolidines Containing Oxidation-Sensitive Functional Groups

Hao-Jie Rong, Yong-Feng Cheng, Fan-Fan Liu, Shu-Jian Ren, and Jin Qu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b02562 • Publication Date (Web): 02 Dec 2016

Downloaded from <http://pubs.acs.org> on December 2, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.




ACS Publications

Synthesis of γ -Lactams by Mild, *o*-Benzoquinone-Induced Oxidation of Pyrrolidines Containing Oxidation-Sensitive Functional Groups

Hao-Jie Rong,[†] Yong-Feng Cheng,[†] Fan-Fan Liu, Shu-Jian Ren, and Jin Qu*

The State Key Laboratory and Institute of Elemento-organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin 300071, China



ABSTRACT: The late-stage oxidation of substituted pyrrolidines offers good flexibility for the construction of γ -lactam libraries, especially in recent years the methods for functionalization of pyrrolidine have been available. We reported a new strategy for oxidation of pyrrolidines to γ -lactams: reaction of pyrrolidine with an *o*-benzoquinone gives an *N,O*-acetal by direct oxidation of the α -C–H bond of the pyrrolidine ring, and then the *N,O*-acetal is further oxidized by the *o*-benzoquinone to the γ -lactam. Because the first oxidation occurs selectively at the α -C–H of the pyrrolidine ring, oxidation-sensitive functional groups (allyl-, vinyl-, hydroxyl-, and amino groups) on pyrrolidine ring are unaffected. The synthetic utility of this novel method was demonstrated by the facile syntheses of (*S*)-vigabatrin and two analogs.

Introduction

The γ -lactam is a heterocyclic moiety that is widespread in bioactive natural products,¹ such as lactacystin^{1a,b} and salinosporamide A.^{1c} In addition, γ -lactams are synthetic precursors of therapeutic analogs of γ -aminobutyric acid, a major inhibitory neurotransmitter in the central nervous system of mammals.² Some γ -aminobutyric acid analogs, such as vigabatrin^{2c} and pregabalin,^{2d} have been commercialized as antiepileptic agents (Chart 1).




Chart 1. γ -Lactam Natural Products and γ -Aminobutyric Acid Drugs.

Various methods have been developed for γ -lactam synthesis.³ Among them, late-stage oxidation of substituted pyrrolidines offers good flexibility for the construction of γ -lactam libraries, especially in recent years the methods for functionalization of pyrrolidine have been available.⁴ However, the chemoselective oxidation of α -C-H of pyrrolidine ring is difficult to achieve. In some of the literatures, the NH of the pyrrolidine was protected prior to oxidation by, for example, RuO_4 ,⁵ CrO_3 ,⁶ Mn(III)/PhIO ,⁷ $\text{Fe(ClO}_4)_2/\text{H}_2\text{O}_2$,⁸ or FeSO_4/t -butyl hydroperoxide,⁹ diacetoxyiodobenzene/ t -butyl hydroperoxide¹⁰ and subsequently deprotected to afford the corresponding γ -lactam (Scheme 1a). There are a few reports of direct conversion of unprotected pyrrolidines to γ -lactams by oxidation with iodosobenzene,^{11a} $[\text{Au}]/\text{O}_2$,^{11b} or $[\text{Ru}]/\text{H}_2\text{O}$ (Scheme 1b).^{11c,d} Also the current oxidations of protected or unprotected pyrrolidines lack chemoselectivities, oxidations only work with unsubstituted, alkyl, acetal, or ester-substituted heterocyclic amines, and oxidation-sensitive functional groups (alkenes and hydroxy and amino groups) are not tolerated.


Quinones, which are important organic oxidizing reagents and redox shuttles, have broad applications in both industry and the research laboratory.¹² Quinones with high reduction potentials (DDQ and chloranil) often mediate hydride abstractions from benzylic or allylic positions.¹³ Quinones with low reduction potentials (such as *o*-quinone cofactors in copper amine oxidases (CAOs)) mediate oxidations of primary amines to aldehydes by molecular oxygen.¹⁴ Secondary amines often inhibit *o*-quinone cofactors because of the formation of irreversible covalent adducts following the transamination mechanism.¹⁵ Recently, *o*-quinone catalyzed dehydrogenations of secondary amines have been achieved by Stahl et al. through the addition-elimination mechanism.¹⁶ We recently found that the redox-neutral oxidation¹⁷ of pyrrolidine by 3,5-di-*tert*-butyl-*o*-benzoquinone in 2,2,2-trifluoroethanol (TFE) transiently generated a *N,O*-acetal and the afterward nucleophilic ring-opening of the *N,O*-acetal could afford 2-functionalized or 2,5-difunctionalized pyrrolidines.¹⁸ During the course of our work, we found that treatment of pyrrolidine with an excess of the quinone results in the formation of small amounts of *N*-aryl-pyrrolidin-2-ones. In this work, we investigate this phenomenon and report a new strategy for oxidation of pyrrolidines to γ -lactams (Scheme 1c): specifically, reaction of pyrrolidine with an *o*-benzoquinone under mild reaction condition initially gives an *N,O*-acetal by direct oxidation of the α -C-H bond of the pyrrolidine ring, and

then the *N,O*-acetal is further oxidized by the *o*-benzoquinone to the γ -lactam.¹⁹ Because the first oxidation occurs selectively at the α -C-H of the pyrrolidine ring, other oxidation-sensitive functional groups on the pyrrolidine ring are unaffected.


Scheme 1. Oxidative Transformations of Pyrrolidines to γ -Lactams

Previous work

(a) Oxidation of *N*-Acyl-pyrrolidines




(b) Direct Oxidation of Pyrrolidines



This work


(c) Chemoselective Oxidation of Pyrrolidines



Results and Discussion



Firstly, we investigated how pyrrolidine was oxidized to *N*-aryl-pyrrolidin-2-one by *o*-benzoquinone in fluorinated alcohol. The first step of this process, the reaction of 3,5-di-*tert*-butyl-*o*-benzoquinone (**1**) with 2-substituted pyrrolidine **2** (Scheme 2), is similar to the reaction of *o*-quinone cofactors in copper amine oxidases.¹⁴ Specifically, the condensation of the pyrrolidine with the quinone gives iminium intermediate **A**. Tautomerization to iminium intermediate **B** (by means of intramolecular 1,5-proton abstraction) and subsequent cyclization afford *N,O*-acetal **3**. The quinone then acts as a hydride abstractor to oxidize **3** to aromatic iminium intermediate **C**,¹² which is attacked by water to provide *N*-aryl-pyrrolidin-2-one **4**. Fluorinated alcohol could stabilize the positive charged iminium species towards intramolecular cyclization or intermolecular nucleophilic addition.²⁰

Scheme 2. Mechanism of the Oxidation of Substituted Pyrrolidines by *o*-Benzoquinone



Initially, the oxidative reaction was carried out by treatment of pyrrolidine (**2a**) with 2.5 equiv. of 3,5-di-*tert*-butyl-o-benzoquinone (**1**) in TFE, but the reaction took rather long time and the yield of *N*-aryl-pyrrolidin-2-one **4a** was moderate. We found that the reaction of **2a** and **1** in TFE at room temperature finished within 0.5 h and gave quantitative yield of *N,O*-acetal **3a**, but the further oxidation of **3a** in TFE took more than 48 h. Then we screened other solvents, including CH_3OH and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), in the hydride abstraction of *N,O*-acetal **3a** (Scheme 3). The results showed that the combination of HFIP (even high polarity and high ionizing power than TFE) with 3 equiv of water delivered the highest reaction rate and highest yield. But the relatively low pH of HFIP hindered the formation of iminium intermediate **A** and slowed the formation of *N,O*-acetal **3a**. To circumvent this problem, we separated the process into two steps that were conducted in one pot (Scheme 3). First, pyrrolidine **2a** was allowed to react with 1.1 equiv of quinone **1** in TFE at room temperature for 0.5 h to generate *N,O*-acetal **3a**, which was not isolated. Then the TFE was removed by rotary evaporation, and the residue was dissolved in HFIP containing 3 equiv of water. To the resulting solution was added 1.4 equiv of the quinone **1**, and the reaction mixture was stirred at 50 °C for 24 h. This procedure afforded *N*-aryl-pyrrolidin-2-one **4a** in 90% yield.



Scheme 3. One-pot, Two-step Synthesis of *N*-Aryl-2-pyrrolidinone **4a**^a



^aReaction conditions: pyrrolidine **2a** (0.2 mmol) and quinone **1** (0.22 mmol) in TFE (10 mL) were stirred at room temperature for 0.5 h; then TFE was removed, the residue was dissolved in the solvent tested (10 mL), quinone **1** (0.28 mmol) and H₂O (0.6 mmol) were added, and the mixture was stirred at 50 °C; ^b the yield was based on **2a**.


Under these one-pot, two-step conditions, the reactions of pyrrolidines with alkyl, methoxymethyl, benzyl, allyl, vinyl, aryl, and cyclopropyl substituents (**2b–n**) readily gave the corresponding *N*-aryl-pyrrolidin-2-ones (**4b–4n**, Scheme 4). Notably, substrates with a free hydroxyl group or a vicinal diol moiety (**2o–2r**) were tolerated, affording **4o–4r** in 78–94% yields. The first-step oxidation of **2o** occurred selectively at the C-2 position.²¹ According to literature, tautomerization of iminium intermediate **A** to iminium intermediate **B** through the abstraction of the α -H of pyrrolidine is the rate-determining step, this regioselectivity may have resulted from the higher acidity of the C-2 hydrogen due to the nearby 3-hydroxyl group.²² In the reaction of amino-substituted pyrrolidine **2s**, the intermediate *N,O*-acetal underwent a side elimination reaction in HFIP, giving aryl substituted pyrrole as the major product.²³ Therefore, for this substrate, we conducted the second step in TFE. Also tetrachloro-*o*-benzoquinone, which is a stronger hydride abstractor delivered higher yield than **1**. Under the optimized condition, desired product **4s** was obtained in 70% yield. Under the same conditions, **4t** was obtained in 46% yield. Piperidine also reacted but with a much lower reaction rate, the desired product **4u** was obtained with 50% yield (70% conv.) after 72 h.²⁴ A large-scale reaction of **2i** (5 mmol) provided the product in 83% yield, a result that shows the potential synthetic utility of this method.

Scheme 4. Substrate Scope in the Synthesis of *N*-Aryl-2-pyrrolidones **4**^a



^aReaction conditions: Pyrrolidine **2** (0.2 mmol) and quinone **1** (0.22 mmol) in TFE (10 mL) were stirred at room temperature; then TFE was removed, the residue was dissolved in HFIP (10 mL), quinone **1** (0.28 mmol) and H₂O (0.6 mmol) were added, and the mixture was stirred at 50 °C. ^bTetrachloro-*o*-benzoquinone and TFE were used in the second step. ^cpiperidine (0.2 mmol) and quinone (0.5 mmol) was heated in solvent (10 mL, TFE:H₂O = 9:1)

Scheme 5. Removal of the Aryl Moiety from **4**^a




^aReaction conditions: **4** (0.2 mmol) and PIDA (0.22 mmol) in 20 mL of 1:2 (v/v) $\text{H}_2\text{O}/\text{MeCN}$. ^bPIFA was used.

Treating *N*-aryl-2-pyrrolidones **4** with phenyliodinediacetate (PIDA) or phenyliodine bis(trifluoroacetate) (PIFA) in a mixture of H_2O and MeCN for 5 min removed the aryl moieties²⁵ to afford substituted γ -lactams **5** in good to excellent chemical yields (Scheme 5).

The synthetic utility of this method was further demonstrated by the synthesis of chiral γ -aminobutyric acid (*S*)-vigabatrin and two analogs (Scheme 6).²⁶ Oxidation, Wittig reaction of commercially available *N*-Boc-*L*-prolinol (**6**, optical purity ee: 99%) gave (*S*)-2-vinyl pyrrolidine **7a**, which was readily transformed to corresponding γ -lactam **8a** by the method described herein. No loss of enantiomeric purity was observed. Hydrolysis of **8a** led to (*S*)-vigabatrin (**9a**). Our late-stage oxidation strategy was also applicable to the synthesis of optical active vigabatrin analogs **9b** and **9c**.

Scheme 6. Synthesis of (*S*)-Vigabatrin and Two Analogs.



Conclusion

In summary, by means of a strategy involving direct oxidation of the $\alpha\text{-C-H}$ of pyrrolidines with an *o*-benzoquinone, we realized the chemoselective oxidation of pyrrolidines with alkene, hydroxyl, and amino substituents to the corresponding γ -lactams. Following the late-stage functionalization and oxidation strategy, we synthesized chiral γ -aminobutyric acid

drug (*S*)-vigabatrin and its two analogs. The mildness and operational simplicity of this novel method make it an excellent tool for late-stage oxidation of substituted pyrrolidines to γ -lactams.

Experimental Section

General Information. Unless specially indicated, all reactions were carried out in aerial atmosphere. All reagents were used without any further purification. Flash column chromatographies were performed on silica gel (200–300 mesh). ^1H , ^{13}C spectra were measured on a NMR instrument (400 MHz for ^1H NMR; 100 MHz for ^{13}C NMR). Chemical shifts of ^1H NMR spectra were recorded relative to internal standard or residual solvent resonance (TMS δ 0.00; CDCl_3 : δ 7.26; D_2O : δ 4.79; CD_3OD : δ 3.31). The following abbreviations were used to express the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad. Chemical shifts of ^{13}C NMR spectra were recorded relative to solvent resonance (CDCl_3 : δ 77.0). HPLC analysis was conducted using Shimadzu LC-20AT with a UV detector SPD-20A and chiral column of CHIRALPAK AD-H (25 cm \times 0.46 cm), CHIRALCEL OD-H (25 cm \times 0.46 cm). Optical rotations were determined at indicated temperature and solvents. High-resolution mass spectral analyses were performed on a high resolution ESI-FTICR mass spectrometer.

Preparation and Characterization of Substrates.

Substrates (**2e**, **2l**, **2m**) were synthesized according to the previously reported method.¹⁸

2-Cyclopropylpyrrolidine Hydrochloride (2e) Cyclopropyl magnesium bromide (0.5 M in THF) was used and the title compound was obtained in 90% yield as a viscous colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 9.84 (s, 0.8H), 9.35 (s, 0.5H), 3.69–3.40 (m, 1H), 3.37–3.23 (m, 1H), 2.93–2.86 (m, 1H), 2.28–2.07 (m, 2H), 2.06–1.81 (m, 2H), 1.28–1.25 (m, 1H), 0.82–0.58 (m, 3H), 0.36 (dt, J = 9.4, 4.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 66.2, 44.4, 30.2, 23.8, 12.2, 4.9, 4.4; HRMS (ESI): calculated for $[\text{C}_7\text{H}_{14}\text{N}]^+$: 112.1121; found: 112.1122.

2-(4-Fluorophenyl)pyrrolidine Hydrochloride (2l) 4-Fluorophenylmagnesium bromide (2.0 M in Et_2O) was used, the title compound was obtained in 75% yield as a viscous yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 9.52 (s, 1H), 8.69 (s, 1H), 7.56 (dd, J = 8.5, 5.1 Hz, 2H), 7.05 (dd, J = 8.8 Hz, 8.5 Hz 2H), 4.56 (brs, 1H), 3.47 (brs, 1H), 3.24 (brs, 1H), 2.41–2.37 (m, 1H), 2.24–2.18 (m, 2H), 2.14–2.01 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 163.18 (d, J = 249.4 Hz), 130.6 (d, J = 8.5 Hz), 129.1 (d, J = 3.2 Hz), 116.1 (d, J = 21.7 Hz), 63.0, 44.8, 31.4, 23.5.

2-(4-Chlorophenyl)pyrrolidine Hydrochloride (2m) Following the synthetic procedure of **2l**, 4-chlorophenylmagnesium bromide (1.0 M in Et_2O) was used, the title compound was obtained in 53% yield as a viscous yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 10.20 (brs, 0.9H), 9.41 (brs, 0.9H), 7.48 (d, J = 7.9 Hz, 2H), 7.33 (d, J = 7.6 Hz, 2H), 4.41 (brs, 1H), 3.38 (brs, 1H), 3.17 (brs, 1H), 2.35 (brs, 1H), 2.16 (brs, 2H), 2.03 (brs, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 135.2, 132.3, 129.5, 129.1, 62.6, 44.7, 31.5, 23.4.

2-(2-Methylprop-1-en-1-yl)pyrrolidine Trifluoroacetate (2j) To the solution of isopropyl triphenylphosphonium iodide (1.7 g, 4 mmol) in THF (40 mL) was added *t*-BuOK (449 mg, 4 mmol) at room temperature under argon. The reaction was stirred at room temperature for 2 h. Then *tert*-butyl-2-formylpyrrolidine-1-carboxylate²⁷ (398 mg, 2 mmol) in THF (10 mL) was added dropwisely. When completed, the reaction was quenched with saturated NH₄Cl, extracted with EtOAc (3X), dried with MgSO₄, and concentrated under reduced pressure. The crude product was purified by column chromatography (EtOAc/PE = 1:9). The product was then dissolved in a solution of TFA (2 mL) and DCM (18 mL) and was stirred at room temperature. Upon completion, the reaction mixture was concentrated to afford the title compound **2j** (324 mg, 73% yield) as a colorless oil; ¹H NMR (400 MHz, CDCl₃): δ 9.70 (brs, 1H), 8.82 (brs, 1H), 5.27 (d, *J* = 9.3 Hz, 1H), 4.43–4.12 (m, 1H), 3.66–3.09 (m, 2H), 2.70 (brs, 1H), 2.24–2.03 (m, 2H), 2.05–1.92 (m, 1H), 1.74 (s, 3H), 1.71 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 141.3, 119.0, 57.8, 44.5, 31.6, 25.7, 23.9, 18.3. HRMS (ESI): calculated for [C₈H₁₅N+H]⁺: 126.1277; found: 126.1274.

Preparation and Characterization of *N*-aryl-2-Pyrrolidones

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4a) To a solution of pyrrolidine (14 mg, 16 μL, 0.2 mmol) in TFE (10 mL) was added 3,5-di-*tert*-butyl-*o*-benziquinone **1** (48 mg, 0.22 mmol) at room temperature. It should be noted that when use pyrrolidine hydrochloride or trifluoroacetate instead of pyrrolidine, K₂CO₃ (2 equiv.) should be added to free the pyrrolidine from its salt (the exact amount of pyrrolidine in its salt should be determined by ¹H NMR). After the reaction was completed in 0.5 h, TFE was evaporated and the residue was dissolved in HFIP (10 mL). Then compound **1** (62 mg, 0.28 mmol) and H₂O (11 mg (11 μL), 0.6 mmol) were added in the above solution and the reaction mixture was heated at 50 °C for 24 h. HFIP was evaporated and the residue was dissolved in DCM (40 mL). The organic layer was washed with brine, dried with MgSO₄ and was concentrated and purified by column chromatography on silica gel using EtOAc/PE = 1: 9 to give **4a** (52 mg, 90% yield) as a light yellow solid. m.p. = 213–215 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.00 (s, 1H), 7.25 (d, *J* = 2.2 Hz, 1H), 6.95 (d, *J* = 2.2 Hz, 1H), 3.98 (t, *J* = 7.0 Hz, 2H), 2.68 (t, *J* = 8.0 Hz, 2H), 2.43–2.13 (m, 2H), 1.44 (s, 9H), 1.29 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 175.8, 147.1, 142.4, 140.3, 128.1, 122.4, 116.4, 51.5, 35.5, 34.5, 32.2, 31.5, 29.9, 19.6; IR(neat): 3061, 2962, 1662, 1482, 1445, 1223, 1199 cm⁻¹; HRMS (MALDI): calculated for [C₁₈H₂₇NO₂+Na]⁺: 312.1934; found: 312.1938.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-methylpyrrolidin-2-one (4b) Following the synthetic procedure of **4a**, 2-methylpyrrolidine was used and the title compound was obtained in 85% yield as a light yellow solid; m.p. = 177–179 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.52 (s, 1H), 7.24 (d, *J* = 2.3 Hz, 1H), 6.89 (d, *J* = 2.3 Hz, 1H), 4.52–4.33 (m, 1H), 2.85–2.58 (m, 2H), 2.53–2.39 (m, 1H), 2.00–1.81 (m, 1H), 1.44 (s, 9H), 1.29 (s, 9H), 1.18 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 175.7, 148.4, 142.4, 140.2, 126.3, 122.4, 117.8, 57.3, 35.4, 34.4, 31.6, 31.2, 29.9, 27.7, 20.1; IR(neat): 3469, 2953, 1669, 1440, 1306 cm⁻¹; HRMS (MALDI): calculated for [C₁₉H₂₉NO₂+Na]⁺: 326.2091; found: 326.2095.

5-Butyl-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4c) Following the synthetic procedure of **4a**, 2-butylpyrrolidine hydrochloride¹⁸ and K₂CO₃ (55 mg, 0.4 mmol) were used and the title compound was obtained in 72% yield as a light yellow solid; m.p. = 82–85 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.52 (s, 1H), 7.24 (d, *J* = 2.2 Hz, 1H), 6.90 (d, *J* = 2.3 Hz, 1H), 4.38–

4.31 (m, 1H), 2.99–2.56 (m, 2H), 2.51–2.34 (m, 1H), 1.98–1.88 (m, 1H), 1.64–1.59 (m, 2H), 1.43 (s, 9H), 1.36–1.12 (m, 4H), 1.28 (s, 9H), 0.79 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 175.8, 148.3, 142.3, 140.2, 126.4, 122.4, 117.9, 61.4, 35.4, 34.4, 32.8, 31.6, 31.2, 29.9, 26.3, 25.0, 22.3, 13.9; IR(neat): 3109, 2956, 2869, 1674, 1586, 1445, 1228 cm^{-1} ; HRMS (MALDI): calculated for $[\text{C}_{22}\text{H}_{35}\text{NO}_2 + \text{Na}]^+$: 368.2560; found: 368.2566.

cis-2-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)octahydro-1H-isoindol-1-one (4d) Following the synthetic procedure of **4t**, octahydro-1H-isoindole was used and the title compound was obtained in 70% yield as a colorless liquid; ^1H NMR (400 MHz, CDCl_3): δ 8.13 (s, 1H), 7.25 (d, $J = 2.4$ Hz, 2H), 6.90 (d, $J = 2.3$ Hz, 1H), 4.07 (dd, $J = 9.6, 5.6$ Hz, 1H), 3.38 (dd, $J = 9.7, 2.1$ Hz, 1H), 2.86–2.74 (m, 1H), 2.59–2.46 (m, 1H), 2.15 (dd, $J = 13.9, 4.1$ Hz, 1H), 1.86–1.74 (m, 1H), 1.72–1.52 (m, 4H), 1.44 (s, 9H), 1.29 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ = 176.9, 147.2, 142.2, 140.3, 128.6, 122.2, 116.1, 55.2, 42.9, 35.5, 34.4, 33.8, 31.6, 29.9, 27.6, 23.5, 22.7. HRMS (ESI): calculated for $[\text{C}_{22}\text{H}_{33}\text{NO}_2 + \text{H}]^+$: 344.2584; found: 344.2588.

5-Cyclopropyl-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4e) Following the synthetic procedure of **4a**, 2-cyclopropylpyrrolidine hydrochloride (**2e**) and K_2CO_3 (55 mg, 0.4 mmol) were used, the title compound was obtained in 75% yield as a light yellow solid; m.p. = 153–154 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.24 (d, $J = 2.2$ Hz, 1H), 7.11 (s, 0.9H), 6.92 (d, $J = 2.3$ Hz, 1H), 3.64 (td, $J = 8.1, 5.5$ Hz, 1H), 2.89–2.56 (m, 2H), 2.46–2.37 (m, 1H), 2.16–1.97 (m, 1H), 1.43 (s, 9H), 1.28 (s, 9H), 0.87–0.85 (m, 1H), 0.41–0.33 (m, 2H), 0.14–0.05 (m, 1H), 0.02–0.00 (m, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ 175.2, 148.3, 141.5, 139.2, 126.2, 122.2, 118.9, 66.4, 35.0, 34.4, 34.0, 31.2, 30.6, 29.5, 25.4, 14.8, 4.8; IR(neat): 3469, 2957, 1673, 1442, 1323 cm^{-1} ; HRMS (MALDI): calculated for $[\text{C}_{21}\text{H}_{31}\text{NO}_2 + \text{Na}]^+$: 352.2247; found: 352.2246.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-(methoxymethyl)pyrrolidin-2-one (4f) Following the synthetic procedure of **4a**, 2-(methoxymethyl)pyrrolidine was used and the title compound was obtained in 75% yield as a light yellow liquid; m.p. = 163–165 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.27 (d, $J = 2.0$ Hz, 1H), 6.91 (s, 0.8H), 6.90 (d, $J = 2.0$ Hz, 1H), 4.12 (brs, 1H), 3.37–3.28 (m, 5H), 2.84–2.66 (m, 1H), 2.42–2.50 (m, 1H), 2.41–2.22 (m, 1H), 2.29–2.06 (m, 1H), 1.42 (s, 9H), 1.28 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 176.2, 149.6, 142.4, 138.3, 124.5, 123.8, 120.5, 72.2, 61.7, 59.1, 35.3, 34.4, 31.6, 31.2, 29.7, 22.2; IR(neat): 3392, 2952, 1681, 1448, 1220 cm^{-1} ; HRMS (MALDI): calculated for $[\text{C}_{20}\text{H}_{31}\text{NO}_3 + \text{Na}]^+$: 356.2196; found: 356.2198.

5-Benzyl-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4g) Following the synthetic procedure of **4a**, 2-benzylpyrrolidine¹⁸ was used and the title compound was obtained in 86% yield as a light yellow solid; m.p. = 130–133 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.61 (s, 0.9H), 7.31–7.24 (m, 3H), 7.23–7.17 (m, 1H), 7.11–7.06 (m, 2H), 7.03 (d, $J = 2.3$ Hz, 1H), 4.68–4.53 (m, 1H), 2.93 (dd, $J = 13.6, 3.8$ Hz, 1H), 2.67–2.53 (m, 2H), 2.51–2.41 (m, 1H), 2.31–2.19 (m, 1H), 2.18–1.93 (m, 1H), 1.46 (s, 9H), 1.32 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 175.8, 148.4, 142.5, 140.5, 136.4, 129.3, 128.6, 126.7, 126.3, 122.6, 117.6, 62.7, 39.4, 35.4, 34.4, 31.6, 30.9, 29.8, 24.2; IR (neat): 3141, 2960, 1671, 1587, 1482, 1233, 761, 699 cm^{-1} ; HRMS (MALDI): calculated for $[\text{C}_{25}\text{H}_{33}\text{NO}_2 + \text{Na}]^+$: 402.2404; found: 402.2405.

5-Allyl-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4h) Following the synthetic procedure of **4a**, 2-allylpyrrolidine hydrochloride¹⁸ and K_2CO_3 (55 mg, 0.4 mmol) were used, the title compound was obtained in 70% yield as a light

yellow solid; m.p. = 136–138 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.45 (s, 0.9H), 7.25 (d, *J* = 2.2 Hz, 1H), 6.93 (d, *J* = 2.2 Hz, 1H), 5.89–5.50 (m, 1H), 5.08 (dd, *J* = 10 Hz, 1.2 Hz 1H), 5.03 (dd, *J* = 9 Hz, 1.2 Hz, 1H), 4.58–4.27 (m, 1H), 2.75–2.57 (m, 2H), 2.45–2.34 (m, 1H), 2.33–2.24 (m, 1H), 2.23–2.13 (m, 1H), 2.07–1.96 (m, 1H), 1.43 (s, 9H), 1.29 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 175.8, 148.4, 142.5, 140.3, 132.1, 126.1, 122.6, 119.1, 117.8, 60.9, 37.5, 35.4, 34.4, 31.5, 31.1, 29.8, 23.9; IR(neat): 3262, 3077, 2967, 1611, 1604, 1479, 1308 cm⁻¹; HRMS (MALDI): calculated for [C₂₁H₃₁NO₂+Na]⁺: 352.2247; found: 352.2250.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-vinylpyrrolidin-2-one (4i) Following the synthetic procedure of **4a**, 2-vinylpyrrolidine hydrochloride⁸ and K₂CO₃ (55 mg, 0.4 mmol) were used, the title compound was obtained in 80% yield as a light yellow solid; m.p. = 130–132 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.62 (s, 1H), 7.21 (d, *J* = 2.1 Hz, 1H), 6.89 (d, *J* = 2.2 Hz, 1H), 5.89–5.53 (m, 1H), 5.25 (d, *J* = 17.1 Hz, 1H), 5.13 (d, *J* = 10.2 Hz, 1H), 4.86–4.79 (m, 1H), 2.67 (t, *J* = 7.8 Hz, 2H), 2.55–2.41 (m, 1H), 2.14–1.91 (m, 1H), 1.43 (s, 9H), 1.26 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 175.9, 147.7, 141.9, 140.0, 137.0, 126.7, 122.2, 118.2, 118.0, 64.7, 35.4, 34.4, 31.4, 31.0, 29.8, 27.1; IR (neat): 3076, 2958, 1655, 1483, 1298 cm⁻¹; HRMS (ESI): calculated for [C₂₀H₂₉NO₂+H]⁺: 316.2271; found: 316.2274.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-(isobutenyl)pyrrolidin-2-one (4j) Following the synthetic procedure of **4a**, 2-(isobutenyl)pyrrolidine trifluoroacetate (**2j**) and K₂CO₃ (55 mg, 0.4 mmol) were used, the title compound was obtained in 73% yield as a light yellow solid; m.p. = 146–148 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.60 (s, 1H), 7.20 (d, *J* = 2.2 Hz, 1H), 6.82 (d, *J* = 2.3 Hz, 1H), 5.09–4.95 (m, 2H), 2.67–2.63 (dd, *J* = 9.0, 6.6 Hz, 2H), 2.48–2.36 (m, 1H), 2.01–1.84 (m, 1H), 1.67 (s, 3H), 1.62 (s, 3H), 1.43 (s, 9H), 1.24 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 175.8, 147.7, 141.8, 139.7, 135.8, 126.8, 124.5, 122.1, 118.1, 60.2, 35.4, 34.3, 31.5, 31.4, 30.0, 27.7, 25.6, 18.1; IR (neat): 3105, 2955, 1688, 1585, 1483, 1297 cm⁻¹; HRMS (MALDI): calculated for [C₂₂H₃₃NO₂+H]⁺: 344.2584; found: 344.2588.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-phenylpyrrolidin-2-one (4k) Following the synthetic procedure of **4a**, 2-phenylpyrrolidine was used and the title compound was obtained in 76% yield as a light yellow solid; m.p. = 52–54 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.68 (s, 1H), 7.30–7.15 (m, 5H), 7.07 (d, *J* = 2.3 Hz, 1H), 6.73 (d, *J* = 2.3 Hz, 1H), 5.51–5.24 (m, 1H), 2.79–2.70 (m, 3H), 2.31–2.01 (m, 1H), 1.40 (s, 9H), 1.09 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 176.3, 147.7, 142.0, 140.6, 140.0, 128.7, 127.8, 126.9, 126.0, 122.0, 117.8, 66.3, 35.3, 34.2, 31.3, 30.7, 29.8; IR (neat): 3679, 2959, 1674, 1279, 758, 698 cm⁻¹; HRMS (MALDI): calculated for [C₂₄H₃₁NO₂+Na]⁺: 388.2247; found: 388.2248.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-(4-fluorophenyl)pyrrolidin-2-one (4l) Following the synthetic procedure of **4a**, 2-(4-fluorophenyl)pyrrolidine hydrochloride (**2l**) and K₂CO₃ (55 mg, 0.4 mmol) were used, the title compound was obtained in 86% yield as a light yellow solid; m.p = 158–160 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.61 (s, 0.9H), 7.2–7.12 (m, 2H), 7.08 (s, 1H), 6.98–6.87 (m, 2H), 6.72 (s, 1H), 5.40 (t, *J* = 6.6 Hz, 1H), 3.01–.60 (m, 3H), 2.28–2.01 (m, 1H), 1.40 (s, 9H), 1.11 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 176.2, 162.2 (d, *J* = 246.5 Hz), 147.8, 142.1, 140.0, 136.3, 127.8 (d, *J* = 8.2 Hz), 126.7, 122.1, 117.7, 115.6 (d, *J* = 21.6 Hz), 65.5, 35.3, 34.2, 31.3, 31.2, 30.7, 29.7; IR (neat): 3124, 2968, 1661, 1605, 1442, 1511, 1229, 839 cm⁻¹; HRMS (ESI): calculated for [C₂₄H₃₀FNO₂+H]⁺: 384.2333; found: 384.2337.

5-(4-Chlorophenyl)-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)pyrrolidin-2-one (4m) Following the synthetic procedure of **4a**, 2-(4-chlorophenyl)pyrrolidine hydrochloride (**2m**) and K_2CO_3 (55 mg, 0.4 mmol) were used, the title compound was obtained in 80% yield as a light yellow liquid; 1H NMR (400 MHz, $CDCl_3$): δ 7.59 (brs, 0.9H), 7.21 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 2.2 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 5.40 (t, J = 7.0 Hz, 1H), 2.87–2.53 (m, 3H), 2.16–1.92 (m, 1H), 1.40 (s, 9H), 1.11 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 176.2, 147.8, 142.2, 140.2, 139.2, 133.6, 128.9, 127.4, 126.7, 122.3, 117.6, 65.5, 35.3, 34.2, 31.3, 31.2, 30.6, 29.7; IR (neat): 3426, 3158, 2957, 1659, 1484, 1441, 1389, 817 cm^{-1} ; HRMS (ESI): calculated for $[C_{24}H_{30}ClNO_2+H]^+$: 400.2038; found: 400.2042.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-(4-methoxyphenyl)pyrrolidin-2-one (4n)

Following the synthetic procedure of **4a**, 2-(4-methoxyphenyl)pyrrolidine trifluoroacetate²⁸ and K_2CO_3 (55 mg, 0.4 mmol) were used, the title compound was obtained in 78% yield as a viscous light yellow liquid; 1H NMR (400 MHz, $CDCl_3$): δ 7.65 (s, 0.9H), 7.16–7.05 (m, 3H), 6.84–6.57 (m, 3H), 5.41–5.28 (m, 1H), 3.73 (s, 3H), 2.80–2.62 (m, 3H), 2.19–1.99 (m, 1H), 1.39 (s, 9H), 1.11 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 176.2, 159.1, 147.8, 141.9, 139.9, 132.6, 127.3, 126.9, 122.0, 117.9, 114.1, 65.7, 55.2, 35.3, 34.2, 31.3, 30.8, 29.8; IR (neat): 3421, 2957, 1651, 1586, 1540, 1390, 1247, 1150, 868 cm^{-1} ; HRMS (MALDI): calculated for $[C_{25}H_{33}NO_3+Na]^+$: 418.2353; found: 418.2358.

The regioselectivity in the *N,O*-acetal formation of pyrrolidin-3-ol (2o)

5,7-di-*tert*-butyl-1,2,3,3a-tetrahydrobenzo[d]pyrrolo[2,1-b]oxazol-3-ol (3o) To a solution of pyrrolidin-3-ol (**2o**, 17 mg, 0.2 mmol) in TFE (10 mL) was added 3,5-di-*tert*-butyl-1,2-benzoquinone (48 mg, 0.22 mmol) at room temperature. After 0.5 h, TFE was evaporated, the residue was purified by chromatography using EtOAc/PE (1:9) to give **3o** (52 mg, 90% yield). The configuration of **3o** was determined by 2D COSY and 2D NOESY. 1H NMR (400 MHz, $CDCl_3$ diastereoisomers (*cis/trans* = 11:9)): δ 6.80 (d, J = 1.8 Hz, 0.45H), 6.78 (d, J = 1.8 Hz, 0.54H), 6.72 (d, J = 1.8 Hz, 0.44H), 6.68 (d, J = 1.8 Hz, 0.51H), 5.87–5.79 (m, 0.55H), 5.67–5.60 (m, 0.46H), 4.46–4.44 (m, 0.45H), 4.4–4.36 (m, 0.55H), 3.70–3.59 (m, 0.48H), 3.51–3.47 (m, 0.61H), 3.23–3.16 (m, 1H), 2.09–1.72 (m, 3H), 1.37 (s, 5H), 1.33 (s, 4H), 1.28 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$ diastereoisomers (*cis/trans* = 11:9)): δ 147.3, 147.0, 144.5, 143.9, 141.5, 141.0, 130.7, 130.5, 116.8, 116.2, 109.5, 108.5, 106.7, 101.5, 71.4, 54.7, 53.0, 34.6, 34.0, 33.99, 31.7, 31.7, 31.5, 31.4, 29.5, 29.4.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-3-hydroxypyrrolidin-2-one (4o) Following the synthetic procedure of **4a**, 3-hydroxypyrrolidine was used, the title compound was obtained in 78% yield as a colorless solid. The regioselectivity of the reaction was determined by 1H - 1H -COSY NMR experiment. m.p = 236–239 $^{\circ}C$; 1H NMR (400 MHz, $CDCl_3$): δ 7.81 (s, 1H), 7.28 (d, J = 2.2 Hz, 1H), 6.93 (d, J = 2.3 Hz, 1H), 4.60 (t, J = 8.7 Hz, 1H), 4.10–3.91 (m, 1H), 3.88–3.71 (m, 1H), 3.25 (s, 1H), 2.66 (dt, J = 12.8, 6.5 Hz, 1H), 2.36–2.19 (m, 1H), 1.44 (s, 9H), 1.29 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.2, 147.1, 142.7, 140.4, 127.5, 123.0, 116.4, 70.2, 47.0, 35.5, 34.4, 31.5, 29.8, 29.2; IR (neat): 3392, 2967, 1664, 1443, 1247, 1110 cm^{-1} ; HRMS (ESI): calculated for $[C_{18}H_{27}NO_3+Na]^+$: 328.1883; found: 328.1885.

(3*R*,5*R*)-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)-5-ethyl-3-hydroxypyrrolidin-2-one (4p) Following the synthetic procedure of **4a**, (3*R*,5*R*)-5-ethylpyrrolidin-3-ol hydrochloride²⁹ and K_2CO_3 (55 mg, 0.4 mmol) were used and the title compound was obtained in 91% yield as a light yellow oil; $[\alpha]_D^{24}$ = –145.6 (c = 1.0, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 7.27 (d, J = 2.2 Hz, 1H), 6.97 (d, J =

2.3 Hz, 1H), 6.95 (s, 1H), 4.65 (dd, $J = 7.6, 6.1$ Hz, 1H), 4.43–4.27 (m, 1H), 3.39 (brs, 0.7H), 2.49–2.23 (m, 2H), 1.66–1.51 (m, 1H), 1.45–1.39 (m, 1H), 1.43 (s, 9H), 1.29 (s, 9H), 0.80 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 175.1, 148.2, 142.7, 139.7, 125.3, 123.2, 118.8, 70.01, 60.3, 35.3, 34.4, 32.8, 31.5, 29.8, 26.0, 8.9; IR (neat): 3421, 2959, 1658, 1446, 1363, 1225, 1103, 1027 cm^{-1} ; HRMS (ESI): calculated for $[\text{C}_{20}\text{H}_{31}\text{NO}_3+\text{H}]^+$: 334.2377, found: 334.2382.

(3*R*,5*S*)-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)-3-hydroxy-5-vinylpyrrolidin-2-one (4q) Following the synthetic procedure of **4a**, (3*R*,5*R*)-5-vinylpyrrolidin-3-ol hydrochloride²⁹ and K_2CO_3 (55 mg, 0.4 mmol) were used and the title compound was obtained in 94% yield as a light yellow solid; m.p. = 53–54 °C; $[\alpha]_{\text{D}}^{24} = -41.6$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.26 (s, 1H), 7.13 (s, 1H), 6.99 (d, $J = 1.9$ Hz, 1H), 5.75 (ddd, $J = 17.3, 10.2, 7.4$ Hz, 1H), 5.19 (d, $J = 17.1$ Hz, 1H), 5.13 (d, $J = 10.3$ Hz, 1H), 4.77 (td, $J = 7.5, 2.7$ Hz, 1H), 4.66 (t, $J = 7.6$ Hz, 1H), 4.10 (s, 1H), 2.47 (dt, $J = 15.4, 7.8$ Hz, 1H), 2.43–2.33 (m, 1H), 1.42 (s, 9H), 1.26 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 175.3, 147.6, 142.6, 140.0, 136.3, 126.1, 123.0, 118.5, 117.9, 69.5, 62.0, 35.7, 35.4, 34.4, 31.4, 29.8; IR (neat): 3421, 2957, 1665, 1482, 1442, 1362, 1200, 1107, 927 cm^{-1} ; HRMS (ESI): calculated for $[\text{C}_{20}\text{H}_{29}\text{NO}_3+\text{H}]^+$: 332.2220, found: 332.2225.

Trans-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)-3,4-dihydroxypyrrolidin-2-one (4r) Following the synthetic procedure of **4t**, *trans*-3,4-dihydroxypyrrolidine was used, the title compound was obtained in 80% yield as a yellow solid. m.p = 204.5–206.0 °C; ^1H NMR (400 MHz, CD_3OD): δ 7.28 (s, 1H), 7.01 (s, 1H), 4.41–4.29 (m, 2H), 3.80 (t, $J = 8.3$ Hz, 1H), 3.69–3.58 (m, 1H), 1.41 (s, 9H), 1.29 (s, 9H); ^{13}C NMR (100 MHz, CD_3OD): δ 173.9, 148.0, 142.3, 138.6, 126.4, 122.8, 119.3, 76.1, 72.5, 53.2, 34.9, 33.9, 30.5, 28.8; HRMS (MALDI): calculated for $[\text{C}_{18}\text{H}_{27}\text{NO}_4+\text{Na}]^+$: 344.1832; found: 344.1835.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-3-(methylamino)pyrrolidin-2-one (4s) Following the same procedure for **4t**, 3-(methylamino)pyrrolidine trifluoroacetate and K_2CO_3 (55 mg, 0.4 mmol) were used, the title compound was obtained in 70% yield as a light yellow solid and **4s'** was obtained in 6% yield as a light yellow solid; ^1H NMR (400 MHz, CDCl_3): δ 7.27 (d, $J = 2.1$ Hz, 1H), 6.94 (d, $J = 2.1$ Hz, 1H), 4.08–3.92 (m, 1H), 3.84–3.75 (m, 1H), 3.70–3.60 (m, 1H), 2.53 (s, 3H), 2.53–2.47 (m, 1H), 2.24–2.01 (m, 1H), 1.44 (s, 9H), 1.29 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 175.0, 147.2, 142.5, 140.2, 127.71, 122.74, 116.5, 60.8, 48.0, 35.5, 34.5, 33.8, 31.5, 29.8, 27.0; IR (neat): 3298, 3064, 1698, 1483, 1285 cm^{-1} ; HRMS (MALDI): calculated for $[\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_2+\text{H}]^+$: 319.2380, found: 319.2385.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl) pyrrole (4s') ^1H NMR (400 MHz, CDCl_3): δ 7.34 (d, $J = 2.2$ Hz, 1H), 7.10 (d, $J = 2.3$ Hz, 1H), 6.89–6.77 (m, 2H), 6.49–6.35 (m, 2H), 5.21 (s, 1H), 1.43 (s, 9H), 1.30 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 145.0, 142.3, 136.3, 127.9, 123.6, 122.1, 121.5, 110.4, 35.3, 34.4, 31.5, 29.5; IR(neat): 3511, 3458, 2959, 1598, 1488, 1416, 1392, 1234 cm^{-1} .

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-3-(dimethylamino)pyrrolidin-2-one (4t) The synthetic procedure was same as **4a**, except that 3-(*N,N*-dimethylamino)pyrrolidine was consumed after 1 h in the first step. In the second step, 1,2,3,4-tetrachloro-*o*-benzoquinone (0.28 mmol, 69 mg) and H_2O (11 μL , 0.6 mmol) were added and the reaction was heated at 50 °C until the consumption of the *N,O*-acetal. Next TFE was evaporated and the residue was dissolved in DCM (40 mL). The crude reaction mixture was washed with brine, dried with MgSO_4 and concentrated under reduced pressure, the crude product was purified by col-

umn chromatography on silica gel using EtOAc/ PE = 1:6 to afford **4t** (46% yield) and **4s'** (26% yield).

4t: colorless solid; m.p. = 131–133 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.89 (s, 0.9H), 7.26 (brs, 1H), 6.92 (brs, 1H), 4.13–3.90 (m, 1H), 3.87–3.66 (m, 2H), 2.50 (s, 6H), 2.39–2.20 (m, 2H), 1.44 (s, 9H), 1.28 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 173.9, 147.1, 142.5, 140.4, 128.0, 122.6, 116.2, 65.7, 47.7, 41.5, 35.5, 34.4, 31.5, 29.8, 21.4; IR (neat): 3728, 2924, 2854, 1699, 1481, 1389, 1360, 1201 cm⁻¹; HRMS (MALDI): calculated for [C₂₀H₃₂N₂O₂ + Na]⁺: 355.2356, found: 355.2358.

1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)piperidin-2-one (4u) A solution of piperidine (0.2 mmol, 17 mg) and 3,5-di-*tert*-butyl-*o*-benzoquinone (0.5 mmol, 110 mg) in the mixed solvent of TFE (9 mL) and H₂O (1 mL) was heated at 80 °C and the reaction was monitored by TLC. After 72 h, TFE was evaporated and the residue was dissolved in DCM (40 mL), the crude reaction mixture was washed with brine and dried with MgSO₄ and concentrated. The crude product was further purified by chromatography using EtOAc/PE = (1:4) to give the title compound **4u** (30 mg) in 50% yield as yellow solid; m.p. = 181–183 °C ¹H NMR (400 MHz, CDCl₃): δ 7.01 (s, 1H), 6.90 (s, 1H), 3.74 (s, 2H), 2.64 (s, 2H), 1.95 (s, 4H), 1.43 (s, 9H), 1.27 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 171.5, 147.6, 142.9, 139.8, 132.6, 122.8, 118.9, 52.3, 35.4, 34.5, 32.5, 31.5, 29.9, 23.4, 20.8; HRMS (ESI): calculated for [C₁₉H₂₉NO₂ + Na]⁺: 326.2091, found: 326.2095.

***N*-Dearylation of *N*-Aryl-2-Pyrrolidones²⁵**

2-Pyrrolidinone (5a)^{11c} To the solution of **4a** (58 mg, 0.2 mmol) in the mixed solvent of H₂O and MeCN (20 mL, H₂O/MeCN = 1/2 (v:v)) was added PIDA (71 mg, 0.22 mmol) at room temperature. Upon completion, MeCN was evaporated. Saturated NaHCO₃ (2 mL) was added to the reaction mixture. The resulted reaction mixture was extracted with mixed solvent of CHCl₃ and 2-propanol (CHCl₃/2-propanol (v:v = 3:1)) three times. The combined organic phase was dried with MgSO₄ and concentrated. The residue was purified by column chromatography (MeOH/EtOAc = 1:9) to afford **5a** (16 mg, 94% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 6.91 (brs, 1H), 3.41 (t, *J* = 6.9 Hz, 2H), 2.31 (t, *J* = 8.1 Hz, 2H), 2.21–2.01 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 179.3, 42.2, 30.0, 20.7.

5-Methyl-2-pyrrolidinone (5b)^{11c} Following the same procedure for **5a**, the title compound was obtained in 92% yield as a colorless oil; ¹H NMR (400 MHz, CDCl₃): δ 6.43 (brs, 1H), 4.06–3.61 (m, 1H), 2.43–2.32 (m, 2H), 2.3–2.23 (m, 1H), 1.77–1.50 (m, 1H), 1.23 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 178.6, 50.2, 30.6, 29.0, 22.1.

5-Benzyl-2-pyrrolidinone (5g)³⁰ To the solution of **4g** (76 mg, 0.2 mmol) in the mixed solvent of H₂O and MeCN (20 mL, H₂O/MeCN = 1/4 (v:v)) was added PIFA (95 mg, 0.22 mmol). Upon completion, MeCN was evaporated. Saturated NaHCO₃ (2 mL) was added to the reaction mixture. The resulted reaction mixture was then extracted with the mixed solvent of CHCl₃ and 2-propanol (CHCl₃/2-propanol (v:v = 3:1)) three times. The combined organic phase was dried with MgSO₄ and concentrated. The residue was purified by column chromatography (MeOH/EtOAc = 1:9) to give the title compound (30 mg) in 85% yield as a colorless solid; m.p. = 57–58 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.36–7.29 (m, 2H), 7.28–7.24 (m, 1H), 7.2–7.15 (m, 2H), 6.05 (s, 1H), 4.07–3.81 (m, 1H), 2.84 (dd, *J* = 13.4, 5.6 Hz, 1H), 2.73 (dd, *J* = 13.4, 8.0 Hz, 1H), 2.36–2.29 (m, 2H), 2.29–2.20 (m, 1H), 1.93–1.76 (m, 1H);

¹³C NMR (100 MHz, CDCl₃): δ 178.1, 137.5, 129.1, 128.8, 126.9, 55.8, 43.0, 30.1, 26.9.

5-Allyl-2-pyrrolidinone (5h)³¹ Following the same procedure for **5g**, the title compound was obtained in 98% yield as a colorless oil; ¹H NMR (400 MHz, CDCl₃): δ 7.03 (s, 0.8H), 5.92–5.57 (m, 1H), 5.14 (d, *J* = 4.4 Hz, 1H), 5.10 (s, 1H), 3.83–3.66 (m, 1H), 2.51–2.36 (m, 2H), 2.33–2.16 (m, 3H), 1.95–1.67 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 179.0 133.45, 118.5, 54.1, 40.8, 30.3, 26.4.

5-Vinyl-2-pyrrolidinone (5i)³² To a solution of **4i** (63 mg, 0.2 mmol) in the mixed solvent H₂O and CH₃CN (20 mL, H₂O/CH₃CN = 1:4 (v:v)) was added K₂CO₃ (28 mg, 0.2 mmol). Then PIFA (95 mg, 0.22 mmol) was added at room temperature. Upon completion, MeCN was evaporated. Saturated NaHCO₃ (2 mL) was added to the reaction mixture. The aqueous layer was extracted with the mixed solvent of CHCl₃ and 2-propanol (CHCl₃/2-propanol (v:v = 3:1)) three times. The combined organic phase was dried with MgSO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (MeOH/EtOAc =1:9) to give the title compound in 85% yield as a viscous colorless solid; ¹H NMR (400 MHz, CDCl₃): δ 6.21 (brs, 1H), 5.81 (ddd, *J* = 17.0, 10.2, 6.8 Hz, 1H), 5.23 (d, *J* = 17.0 Hz, 1H), 5.13 (d, *J* = 10.2 Hz, 1H), 4.24–4.01 (m, 1H), 2.45–2.26 (m, 3H), 2.05–1.73 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 178.7, 138.6, 115.6, 56.7, 29.9, 27.9.

5-Phenyl-2-pyrrolidinone (5k)³³ Following the same procedure for **5i**, the title compound was obtained in 68% yield as a colorless solid; m.p. = 103–104 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.43–7.34 (m, 2H), 7.33–7.25 (m, 3H), 6.31 (brs, 0.9H), 4.76 (t, *J* = 7.1 Hz, 1H), 2.67–2.52 (m, 1H), 2.51–2.37 (m, 2H), 2.05–1.92 (m, 1H); ¹³C NMR (100MHz, CDCl₃): δ 178.6, 142.5, 128.9, 128.0, 125.7, 58.1, 31.4, 30.3.

3-Hydroxy-2-pyrrolidinone (5o)³⁴ The synthetic procedure was same as **5a** except that after MeCN in the reaction mixture was evaporated, the aqueous layer was washed with hexane for three times. Water in the aqueous phase was evaporated to give the title compound in 91% yield as a colorless solid with excellent purity; ¹H NMR (400 MHz, CDCl₃): δ 7.21 (brs, 0.9H), 4.72 (s, 1H), 4.36 (t, *J* = 8.4 Hz, 1H), 3.42 (t, *J* = 9.3 Hz, 1H), 3.37–3.24 (m, 1H), 2.60–2.44 (m, 1H), 2.21–1.97 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 179.0, 69.0, 38.8, 29.9.

3-(Methylamino)pyrrolidin-2-one Trifluoroacetate (5s) Following the same procedure for **5g**, except that after MeCN in the reaction mixture was evaporated, the aqueous layer was washed with hexane for three times. Water in the aqueous phase was evaporated to give the title compound with excellent purity in 79% yield as a light brown solid; ¹H NMR (400 MHz, D₂O): δ 4.11 (t, *J* = 9.5 Hz, 1H), 3.54–3.29 (m, 2H), 2.77 (s, 3H), 2.65–2.58 (m, 1H), 2.22–2.10 (m, 1H); ¹³C NMR (100 MHz, D₂O): δ 172.2, 57.6, 39.2, 30.8, 23.8; HRMS (ESI): calculated for [C₅H₁₀N₂O+H]⁺: 115.0866; found: 115.0870.

3-(Dimethylamino)-2-pyrrolidinone (5t) Following the same procedure for **5g**, the title compound was obtained in 98% yield as a light brown solid; ¹H NMR (400 MHz, CDCl₃): δ 6.88 (brs, 0.9H), 3.43 (t, *J* = 8.8 Hz, 1H), 3.39–3.25 (m, 2H), 2.39 (s, 6H), 2.26–2.02 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 176.9, 64.3, 41.4, 39.2, 21.4. HRMS (ESI): calculated for [C₆H₁₂N₂O+H]⁺: 129.1022 ; found: 129.1021.

Synthesis of S-Vigabatrin and Its Analogs

(S)-2-Vinylpyrrolidine Trifluoroacetate (7a) To a solution of methyltriphenylphosphonium iodide (1.6 g, 4 mmol) in Et₂O (40 mL) was added *t*-BuOK (449 mg, 4 mmol) at room temperature under argon. After stirred 2 h at room temperature, Boc-(S)-pyrrolidine-2-carbaldehyde **6a**²⁷ (398 mg, 2 mmol) in Et₂O (10 mL) was added dropwisely. Upon completion, the reaction was quenched by saturated NH₄Cl. The reaction mixture was extracted with EtOAc three times. The combined organic phase was dried with MgSO₄ and concentrated under reduced pressure. The residue was purified by chromatography (hexane/EtOAc = 1:1). Then the residue was dissolved in the solution of TFA and DCM (20 mL, TFA:DCM = 1:9 (v:v)) and stirred at room temperature. When completed, evaporation of the solvent gave **7a** (373 mg, 96% yield) as a colorless oil, which spectroscopic data was identical with compound **2i**; [α]_D²⁴ = -3.0 (c = 0.28, MeOH/H₂O = 1:1).

(S)-1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-vinyl-2-pyrrolidinone (10a) Following the same procedure for **4i**, the title compound was obtained in 82% yield as a light yellow solid, which spectroscopic data was identical with compound **4i**; [α]_D²⁴ = -204.0 (c = 0.20, CHCl₃).

(S)-5-Vinyl-2-pyrrolidinone (8a)³² Following the same procedure for **5i**, the title compound was obtained in 88% yield as a colorless solid, which spectroscopic data was identical with compound **5i**; optical purity ee: 97%; HPLC condition: Chiralpak AD-H column (25 cm × 0.46 cm ID), hexane/2-propanol = 96:4, 0.8 mL/min, 227 nm UV detector, *t*_R = 21.37 min (major) and *t*_R = 25.51 min (minor). [α]_D²⁴ = +34.1 (c = 0.34, CHCl₃).

(S)-4-Amino-5-hexenoic acid Hydrochloride (9a)³² A solution of (S)-5-vinyl-2-pyrrolidinone **8a** (22 mg, 0.2 mmol) in 1M HCl (10 mL) was heated to reflux. When completed, the aqueous phase was washed with EtOAc and concentrated to give the title compound **9a** (33 mg) in 99% yield as a colorless solid; [α]_D²⁴ = -12.0 (c = 0.6, MeOH); ¹H NMR (400 MHz, D₂O): δ 5.79 (ddd, *J* = 17.2, 10.4, 8.4 Hz, 1H), 5.48–5.0 (m, 2H), 3.86–3.80 (m, 1H), 2.72–2.37 (m, 2H), 2.29–2.02 (m, 1H), 2.01–1.83 (m, 1H); ¹³C NMR (100 MHz, D₂O): δ 176.9, 132.3, 121.7, 53.4, 29.7, 27.0.

(S)-1-(3,5-Di-*tert*-butyl-2-hydroxyphenyl)-5-(2,2-dibromovinyl)-2-pyrrolidinone (10b) Following the synthetic procedure of **4a**, (S)-2-(2,2-dibromovinyl)pyrrolidine trifluoroacetate (**7b**)²⁷ and K₂CO₃ (55 mg, 0.4 mmol) were used, the title compound was obtained in 81% yield as a light yellow solid; m.p. = 184–185 °C; [α]_D²⁴ = -67.7 (c = 0.57, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.56 (s, 1H), 7.25 (brs, 1H), 6.82 (brs, 1H), 6.31 (d, *J* = 8.1 Hz, 1H), 5.14–5.08 (m, 1H), 2.85–2.64 (m, 2H), 2.64–2.46 (m, 1H), 2.28–1.77 (m, 1H), 1.44 (s, 9H), 1.30 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 175.5, 147.5, 142.6, 140.3, 137.4, 126.3, 122.7, 117.3, 92.7, 63.7, 35.5, 34.5, 31.6, 31.1, 29.9, 25.6; HRMS (ESI): calculated for [C₂₀H₂₇Br₂NO₂+H]⁺, 472.0481; found: 472.0483.

(S)-5-(2,2-Dibromovinyl)-2-pyrrolidinone (8b) Following the synthetic procedure of **5a**, the title compound was obtained in 75% yield as a colorless solid; m.p. = 122–124 °C; optical purity ee: 99%; HPLC condition: Chiralpak AD-H column (25 cm × 0.46 cm ID), hexane/2-propanol = 96:4, 0.8 mL/min, 227 nm UV detector, *t*_R = 24.40 min (minor) and *t*_R = 29.27 min (major); [α]_D²⁴ = +8.5 (c = 0.26, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 6.46 (d, *J* = 8.1 Hz, 1H), 6.23 (brs, 1H), 4.61–4.21 (m, 1H), 2.56–2.41 (m, 1H), 2.42–2.32

(m, 2H), 1.96–1.86 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 177.8, 138.6, 92.3, 56.1, 29.6, 26.9.

(S)-4-Amino-6,6-dibromo-5-hexenoic acid Hydrochloride (9b) Following the same procedure for **9a**, the title compound was obtained in 98% yield as a colorless solid; $[\alpha]_{\text{D}}^{24} = +10.9$ ($c = 0.44$, MeOH); ^1H NMR (400 MHz, D_2O): δ 6.53 (d, $J = 9.8$ Hz, 1H), 4.15 (td, $J = 10.0, 4.7$ Hz, 1H), 2.69–2.37 (m, 2H), 2.11 (dd, $J = 13.5, 5.0$ Hz, 1H), 1.96 (ddd, $J = 13.7, 10.2, 6.8$ Hz, 1H); ^{13}C NMR (100 MHz, D_2O): δ 176.7, 132.5, 97.5, 52.7, 29.5, 26.9; HRMS (ESI): calculated for $[\text{C}_6\text{H}_9\text{Br}_2\text{NO}_2 + \text{H}]^+$: 285.9073; found: 285.9067.

(S)-2-Cyclopropylpyrrolidine Trifluoroacetate (7c) To the solution of methyltriphenylphosphonium iodide (1.6 g, 4 mmol) in Et_2O (40 mL) was added *t*-BuOK (449 mg, 4 mmol) at room temperature under argon. After stirred at room temperature for 2 h, Boc-(S)-pyrrolidine-2-carbaldehyde **6a**²⁷ (398 mg, 2 mmol) in Et_2O (10 mL) was added dropwisely. Upon completion, the reaction was quenched with saturated NH_4Cl solution. The reaction mixture was extracted with EtOAc three times. The combined organic phase was dried with MgSO_4 and concentrated under reduced pressure. The residue was purified by chromatography (hexane/EtOAc = 1:6) to give the Boc protected (S)-2-vinylpyrrolidine (383 mg, 97%). Then to the solution of CH_2I_2 (1.3 g (0.4 mL), 5 mmol) in DCM was added Et_2Zn (1.0 M in hexane, 2.5 mL, 2.5 mmol) at 20 °C. After stirred 30 minutes at 20 °C, Boc protected (S)-2-vinylpyrrolidine (383 mg, 1.94 mmol) was added. Upon completion, the reaction was quenched by the addition of saturated NH_4Cl solution. The reaction mixture was extracted with EtOAc three times. The combined organic phase was dried with MgSO_4 and concentrated under reduced pressure. The residue was dissolved in the mixed solvent of TFA and DCM (20 mL, TFA:DCM = 1:9 (v:v)) and stirred at room temperature. When completed, the solvent was removed under reduced pressure. The residue was purified by chromatography (DCM/MeOH = 8:1) to give the title compound in 77% yield, which spectroscopic data was identical with compound **2e**; $[\alpha]_{\text{D}}^{24} = +6.9$ ($c = 0.14$, MeOH/ $\text{H}_2\text{O} = 2:1$).

(S)-5-Cyclopropyl-1-(3,5-di-*tert*-butyl-2-hydroxyphenyl)-2-pyrrolidinone (10c)

Following the same procedure for **4e**, the title compound was obtained in 74% yield as a light yellow solid, which spectroscopic data was identical with compound **4e**; $[\alpha]_{\text{D}}^{24} = -186.3$ ($c = 0.58$, CHCl_3).

(S)-5-Cyclopropyl-2-pyrrolidinone (8c) Following the same procedure for **5g**, the title compound was obtained in 68% yield as a colorless solid; optical purity ee: 98%; HPLC condition: Chiralpak AD-H column (25 cm \times 0.46 cm ID), hexane/2-propanol = 96:4, 0.8 mL/min, 227 nm UV detector, $t_{\text{R}} = 20.93$ min (major) and $t_{\text{R}} = 26.92$ min (minor); $[\alpha]_{\text{D}}^{24} = +44$ ($c = 0.20$, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 6.35 (brs, 0.9H), 3.14–2.87 (m, 1H), 2.50–2.22 (m, 3H), 2.01–1.84 (m, 1H), 1.08–0.75 (m, 1H), 0.70–0.44 (m, 2H), 0.39–0.12 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 176.4, 57.7, 28.6, 25.6, 14.5, 1.1, 0.0; HRMS (ESI): calculated for $[\text{C}_7\text{H}_{11}\text{NO} + \text{Na}]^+$: 148.0733; found: 148.0734.

(S)-4-Amino-4-cyclopropylbutanoic acid Hydrochloride (9c) Following the same procedure for **9a**, the title compound was obtained in 97% yield as a colorless solid; $[\alpha]_{\text{D}}^{24} = -97.2$ ($c = 0.33$, MeOH); ^1H NMR (400 MHz, D_2O): δ 3.11–2.43 (m, 3H), 2.30–1.94 (m, 2H), 1.04–0.86 (m, 1H), 0.74 (dt, $J = 8.4, 4.7$ Hz, 1H), 0.63 (dd, $J = 12.6, 8.5$ Hz, 1H), 0.45–0.29 (m, 2H); ^{13}C NMR (100 MHz, D_2O): δ 174.9, 54.5, 27.7, 26.0, 10.5, 1.9, 0.0; HRMS (ESI): calculated for $[\text{C}_7\text{H}_{13}\text{NO}_2 + \text{H}]^+$: 144.1019; found: 144.1020.

AUTHOR INFORMATION**ASSOCIATED CONTENT****Supporting Information**

Copies of NMR and HPLC spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION**Corresponding Author**

*E-mail: qujin@nankai.edu.cn

Author Contributions

†These authors contributed equally.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

This work was financially supported by the NSFC (21072098, 21372119, 21121002), and Tianjin Natural Science Foundation (14JCYBJC20200). We thank Prof. Guang-Xin Liang at Nankai University for helpful discussions.

REFERENCES

- (a) Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. *Science* **1995**, *268*, 726–731. (b) Omura, S.; Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. *J. Antibiot.* **1991**, *44*, 113–116. (c) Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. *Angew. Chem., Int. Ed.* **2003**, *42*, 355–357. (d) Sakai, R.; Oiwa, C.; Takaishi, K.; Kamiya, H.; Tagawa, M. *Tetrahedron Lett.* **1999**, *40*, 6941–6944.
- (a) Li, K.; Xu, E. *Neurosci. Bull.* **2008**, *24*, 195–200. (b) Ordóñez, M.; Cativiela, C. *Tetrahedron: Asymmetry* **2007**, *18*, 3–99. (c) Lippert, B.; Metcalf, B. W.; Jung, M. J.; Casara, P. *Eur. J. Biochem.* **1977**, *74*, 441–445. (d) Sills, G. J. *Curr. Opin. Pharmacol.* **2006**, *6*, 108–113. (e) Costantino, G.; Macchiarulo, A.; Guadix, A. E.; Pellicciari, R. *J. Med. Chem.* **2001**, *44*, 1827–1832.
- (a) Ye, L.-W.; Shu, C.; Gagosz, F. *Org. Biomol. Chem.* **2014**, *12*, 1833–1845, and references cited therein. For selected recent syntheses of γ -lactams, see: (b) Alcaide, B.; Almendros, P.; Cabrero, G.; Ruiz, M. P. *Org. Lett.* **2005**, *7*, 3981–3984. (c) Van Brabandt, W.; De Kimpe, N. *J. Org. Chem.* **2005**, *70*, 8717–8722. (d) Comesse, S.; Sanselme, M.; Daïch, A. *J. Org. Chem.* **2008**, *73*, 5566–5569. (e) Romero, A.; Woerpel, K. A. *Org. Lett.* **2006**, *8*, 2127–2130. (f) Clarke, L. A.; Ring, A.; Ford, A.; Sinha, A. S.; Lawrence, S. E.; Maguire, A. R. *Org. Biomol. Chem.* **2014**, *12*, 7612–7628. (g) Candeias, N. R.; Gois, P. M. P.; Afonso, C. A. M. *J. Org. Chem.* **2006**, *71*, 5489–5497.

4. (a) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, B. U. W. *Chem. - Eur. J.* **2012**, *18*, 10092–10142. (b) Campos, K. R. *Chem. Soc. Rev.* **2007**, *36*, 1069–1084.
5. (a) Sheehan, J. C.; Tulis, R. W. *J. Org. Chem.* **1974**, *39*, 2264–2267. (b) Yoshifuji, S.; Tanaka, K.; Kawai, T.; Nitta, Y. *Chem. Pharm. Bull.* **1985**, *33*, 5515–5521. (c) Yoshifuji, S.; Tanaka, K.; Kawai, T.; Nitta, Y. *Chem. Pharm. Bull.* **1986**, *34*, 3873–3878.
6. Blay, G.; Cardona, L.; García, B.; García, C. L.; Pedro, J. R. *Tetrahedron Lett.* **1997**, *38*, 8257–8260.
7. Punniyamurthy, T.; Katsuki, T. *Tetrahedron* **1999**, *55*, 9439–9454.
8. Murata, S.; Miura, M.; Nomura, M. *J. Chem. Soc., Perkin Trans. 1*, **1987**, 1259–1262.
9. Wei, Y.; Ding, H.; Lin, S.; Liang, F. *Org. Lett.* **2011**, *13*, 1674–1677.
10. Zhao, Y.; Ang, J. Q. L.; Ng, A. W. T.; Yeung, Y.-Y. *RSC Adv.* **2013**, *3*, 19765–19768.
11. (a) Moriarty, R. M.; Vaid, R. K.; Duncan, M. P.; Ochiai, M.; Inenaga, M.; Nagao, Y. *Tetrahedron Lett.* **1988**, *29*, 6913–6916. (b) Klobukowski, E. R.; Mueller, M. L.; Angelici, R. J.; Woo, L. K. *ACS Catal.* **2011**, *1*, 703–708. (c) Khusnutdinova, J. R.; Ben-David, Y.; Milstein, D. *J. Am. Chem. Soc.* **2014**, *136*, 2998–3001. (d) Gellrich, U.; Khusnutdinova, J. R.; Leitun, G. M.; Milstein, D. *J. Am. Chem. Soc.* **2015**, *137*, 4851–4859.
12. For reviews of quinone-mediated oxidations see: Wendlandt, A. E.; (a) Stahl, S. S. *Angew. Chem. Int. Ed.* **2015**, *54*, 14638–14658. (b) Piera, J.; Bäckvall, J.-E. *Angew. Chem. Int. Ed.* **2008**, *47*, 3506–3523.
13. (a) Cosner, C. C.; Cabrera, P. J.; Byrd, K. M.; Thomas, A. M. A.; Helquist, P. *Org. Lett.* **2011**, *13*, 2071–2073. (b) Sharma, G. V. M.; Lavanya, B.; Mahalingam, A. K.; Krishna, P. R. *Tetrahedron Lett.* **2000**, *41*, 10323–10326. (c) Muramatsu, W.; Nakano, K. *Org. Lett.* **2014**, *16*, 2042–2045. (d) Miyamura, H.; Maehata, K.; Kobayashi, S. *Chem. Commun.* **2010**, *46*, 8052–8054.
14. (a) Klinman, J. P.; Bonnot, F. *Chem. Rev.* **2014**, *114*, 4343–4365. (b) Mure, M.; Mills, S. A.; Klinman, J. P. *Biochemistry* **2002**, *41*, 9269–9278. (c) Mure, M. *Acc. Chem. Res.* **2004**, *37*, 131–139.
15. Lee, Y. H.; Huang, H.; Sayre, L. M. *J. Am. Chem. Soc.* **1996**, *118*, 7241–7242.
16. (a) Wendlandt, A. E.; Stahl, S. S. *J. Am. Chem. Soc.* **2014**, *136*, 506–512. (b) Wendlandt, A. E.; Stahl, S. S. *J. Am. Chem. Soc.* **2014**, *136*, 11910–11913. (c) Qin, Y.; Zhang, L.; Lv, J.; Luo, S.; Cheng, J.-P. *Org. Lett.* **2015**, *17*, 1469–1472. (d) Goriya, Y.; Kim, H. Y.; Oh, K. *Org. Lett.* **2016**, *18*, 5174–5177.
17. (a) Richers, M. T.; Breugst, M.; Platonova, A. Y.; Ullrich, A.; Dieckmann, A.; Houk, K. N.; Seidel, D. *J. Am. Chem. Soc.* **2014**, *136*, 6123–6135; (b) Peng, B.; Maulide, N. *Chem. Eur. J.* **2013**, *19*, 13274–13287; (c) Jurberg, I. D.; Peng, B.; Wöstefeld, E.; Wasserloos, M.; Maulide, N. *Angew. Chem. Int. Ed.* **2012**, *51*, 1950–1953; (d) Seidel, D. *Acc. Chem. Res.* **2015**, *48*, 317–328.
18. Cheng, Y.-F.; Rong, H.-J.; Yi, C.-B.; Yao, J.-J.; Qu, J. *Org. Lett.* **2015**, *17*, 4758–4761.
19. Compared to studies of acetal oxidation, studies of *N,O*-acetal oxidation are limited in number. There are two reports on the oxidation of *N,O*-acetals to pyrrolidin-2-ones, one involving bromine and the other involving KMnO_4 : (a) Lienard, P.; Varea, T.; Quirion, J.-C.; Husson, H.-P. *Synlett* **1994**, *1994*, 143–144. (b) François, D.; Poupon, E.; Kunesch, N.; Husson, H.-P. *Eur. J. Org. Chem.* **2004**, 4823–4829.

20. For the properties and applications of fluorinated alcohols, see: (a) Bégué, J.-P.; Bonnet-Delpon, D.; Crousse, B. *Synlett* **2004**, 18–29. (b) Shuklov, I.; Dubrovina, N.; Börner, A. *Synthesis* **2007**, 2925–2943. (c) Yuan, C.; Liang, Y.; Hernandez, T.; Berriochoa, A.; Houk, K. N.; Siegel, D. *Nature* **2013**, 499, 192–196. (d) Acharya, A.; Anumandla, D.; Jeffrey, C. S. *J. Am. Chem. Soc.* **2015**, 137, 14858–14860. (e) Dragan, A.; Kubczyk, T. M.; Rowley, J. H.; Sproules, S.; Tomkinson, N. C. O. *Org. Lett.* **2015**, 17, 2618–2621. (f) Tian, Y.; Xu, X.; Zhang, L.; Qu, J. *Org. Lett.* **2016**, 18, 268–271. (g) Liu, W.; Wang, H.; Li, C. J. *Org. Lett.* **2016**, 18, 2184–2187. (h) Zhang, F.-L.; Hong, K.; Li, T.-J.; Park, H.; Yu, J.-Q. *Science* **2016**, 351, 252–256.
21. See Supporting Information for determination of the structure of **30**.
22. Lee, Y.; Ling, K.-Q.; Lu, X.; Silverman, R. B.; Shepard, E. M.; Dooley, D. M.; Sayre, L. M. *J. Am. Chem. Soc.* **2002**, 124, 12135–12143.
23. See experimental section for details.
24. The relatively low yield of piperidine was probably due to the low efficiency in the formation of the intermediate **A**. Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. *Chem. Rev.* **2007**, 107, 5471–5569.
25. (a) Deng, Y.; Gong, W.; He, J.; Yu, J.-Q. *Angew. Chem. Int. Ed.* **2014**, 53, 6692–6695. (b) Nakazaki, A.; Mori, A.; Kobayashi, S.; Nishikawa, T. *Tetrahedron Lett.* **2012**, 53, 7131–7134.
26. For the synthesis of (*S*)-vigabatrin, see: (a) Bao, H.; Tambar, U. K. *J. Am. Chem. Soc.* **2012**, 134, 18495–18498. (b) Gnamm, C.; Franck, G.; Miller, N.; Stork, T.; Brödner, K.; Helmchen, G. *Synthesis* **2008**, 3331–3350. (c) Gheorghe, A.; Schulte, M.; Reiser, O. *J. Org. Chem.* **2006**, 71, 2173–2176. (d) Anderson, C. E.; Overman, L. E. *J. Am. Chem. Soc.* **2003**, 125, 12412–12413. (e) Chandrasekhar, S.; Mohapatra, S. *Tetrahedron Lett.* **1998**, 39, 6415–6418. For the synthesis of (*S*)-vigabatrin analogs, see: (f) Kolb, M.; Barth, J.; Heydt, J.-G.; Jung, M. J. *J. Med. Chem.* **1987**, 30, 267–272.
27. Trybulski, E. J.; Kramss, R. H.; Mangano, R. M.; Rusinko, A. *J. Med. Chem.* **1990**, 33, 3190–3198.
28. Katritzky, A. R.; Luo, Z.; Fang, Y. *Tetrahedron Lett.* **2000**, 41, 9691–9693.
29. Tanaka, K.-i.; Suzuki, H.; Sawanishi, H. *Heterocycles* **1996**, 43, 205–219.
30. Ackermann, J.; Matthes, M.; Tamm, C. *Helv. Chim. Acta* **1990**, 73, 122–132.
31. Bennett, D. J.; Blake, A. J.; Cooke, P. A.; Godfrey, C. R. A.; Pickering, P. L.; Simpkins, N. S.; Walker, M. D.; Wilson, C. *Tetrahedron* **2004**, 60, 4491–4511.
32. Wei, Z.-Y.; Knaus, E. E. *Tetrahedron* **1994**, 50, 5569–5578.
33. Maldaner, A. O.; Pilli, R. A. *Tetrahedron* **1999**, 55, 13321–13332.
34. Pires, R.; Burger, K. *Tetrahedron* **1997**, 53, 9213–9218.